Table 3.
The growth inhibition of 24, 25, 26, and 27 in murine and human cancer cell lines (ED50 (μg/mL) and GI50 (nM)) a.
| Compound | Cell Line b | ||||||
|---|---|---|---|---|---|---|---|
| P388 | NCI-H460 | KM20L2 | DU-145 | BXPC-3 | MCF-7 | SF-268 | |
| 24 | <0.001 (<1.2) | 0.00088 (1.05) | 0.00061 (0.72) | 0.00054 (0.64) | 0.046 (54.6) | 0.00068 (0.81) | 0.00125 (1.48) |
| 25 | 0.031 (42.8) | 0.0160 (22.1) | 0.0077 (10.6) | 0.023 (31.8) | 0.029 (40.1) | 0.0046 (6.35) | 0.029 (40.1) |
| 26 | 0.0026 (3.59) | 0.00036 (0.50) | 0.00025 (0.35) | 0.00030 (0.41) | 0.00031 (0.43) | 0.00014 (0.19) | 0.00016 (0.22) |
| 27 | - | - | - | - | - | - | - |
| (-) | (198.0) | (35.82) | (12.26) | (386.5) | (35.82) | (30.17) | |
a The nanomolar values in brackets are the cytotoxicity concentrations. b The sequence of tumor cell lines: murine lymphocytic leukemia (P388), lung (NCI-H460), colon (KM20L2), prostate (DU-145), pancreas (BXPC-3), breast (MCF-7), and CNS (SF-268).